Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity : a potential diagnostic pitfall in patients with MOG-EM/MOGAD
Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD) is the most important differential diagnosis of both multiple sclerosis and neuromyelitis optica spectrum disorders. A recent proposal for new diagnostic criteria fo...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
---|---|
Dokumenttyp: | Article (Journal) Editorial |
Sprache: | Englisch |
Veröffentlicht: |
13 April 2024
|
In: |
Journal of neurology
Year: 2024, Jahrgang: 271, Heft: 7, Pages: 4660-4671 |
ISSN: | 1432-1459 |
DOI: | 10.1007/s00415-024-12285-5 |
Online-Zugang: | lizenzpflichtig![]() |
Verfasserangaben: | S. Jarius, M. Ringelstein, K. Schanda, K. Ruprecht, M. Korporal-Kuhnke, A. Viehöver, M.W. Hümmert, P. Schindler, V. Endmayr, M. Gastaldi, C. Trebst, D. Franciotta, O. Aktas, R. Höftberger, J. Haas, L. Komorowski, F. Paul, M. Reindl, B. Wildemann |
Zusammenfassung: | Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD) is the most important differential diagnosis of both multiple sclerosis and neuromyelitis optica spectrum disorders. A recent proposal for new diagnostic criteria for MOG-EM/MOGAD explicitly recommends the use of immunoglobulin G subclass 1 (IgG1)- or IgG crystallizable fragment (Fc) region-specific assays and allows the use of heavy-and-light-chain-(H+L) specific assays for detecting MOG-IgG. By contrast, the utility of MOG-IgG3-specific testing has not been systematically evaluated. |
---|---|
Beschreibung: | Gesehen am 27.09.2024 |
Beschreibung: | Online Resource |
ISSN: | 1432-1459 |
DOI: | 10.1007/s00415-024-12285-5 |